Report Details

Global Soft Tissue Sarcoma Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

ID : 7745242
Date : May 2019
Pages : 220 Pages
Industry : Pharmaceutical and Healthcare


Global Soft Tissue Sarcoma Treatment Market:
Global soft tissue sarcoma treatment market estimated to be valued US$ XX Mn in 2018 and poised to grow at CAGR of XX% over 2019-2025. Market for soft tissue sarcoma treatment projected to reach US$ XX Mn by 2025.

Soft tissue sarcoma is the rare and diverse group of cancers that develop from soft tissues such as blood vessels, muscles, fats, nerves, and deep skin tissues etc. There are around 50 different types of soft tissue sarcoma have been identified, the common types of soft tissue sarcoma are liposarcomas which develop from fat cells, and leiomyosarcomas, which arise from smooth muscle tissue. The soft tissue sarcoma can be treated by the combined chemotherapy, radiotherapy, and surgery to remove the tumour. If surgical procedure is not required, chemotherapy alone can be used.



Increase in the prevalence and incidence of different types of cancers, rise in the number of soft tissue sarcoma cases, increase in the R&D activities on drugs and other biological therapies, patent expiry of branded drugs, increase in the healthcare expenditure and rise in quality patient care are expected to fuel the soft tissue sarcoma treatment market over the forecast period. However, high cost for the radiotherapy and chemotherapy, stringent regulatory guidelines, and adverse effects associated with the treatment might hinder the growth of soft tissue sarcoma treatment market over the forecast timeframe.



The soft tissue sarcoma treatment market has been segmented on basis of disease type, treatment type, and end user



Based on the treatment type, soft tissue sarcoma treatment market is segmented into following:

Targeted Therapy
Chemotherapy
Anti-angiogenesis drugs
Radiation Therapy
Internal Radiation Therapy
External Radiation Therapy


Based on the disease type, soft tissue sarcoma treatment market is segmented into following:

Local Sarcoma
Regional Sarcoma
Metastatic Sarcoma


Based on the distribution channel, soft tissue sarcoma treatment market is segmented into following:

Hospitals
Oncology Clinics
Long Term Care Centres


Soft tissue sarcoma treatment market is in growing stage as very fewer products in the market are currently approved to treat various types of soft tissue sarcoma. Various international companies are very active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license and co-development agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. Merck KGaA paid US$ 110 Mn as upfront payment and milestone payments to Threshold, and additionally, Merck KGaA covers 70% of all evofosfamide development expenses. GSK’s Votrient pazopanib is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.



Geographically, soft tissue sarcoma treatment market segmented into following regions Viz. North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America may lead the soft tissue sarcoma treatment market owing to increase in the prevalence of the disease. According to American Cancer Society, approximately 12,390 people in 2016 are suffering soft tissue sarcoma and cancer. Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. Asia-Pacific region accounts for a significant growth due to increase in cancer cases, and rise in awareness about advanced soft tissue sarcoma treatment.



Some of the players in the soft tissue sarcoma treatment market are GlaxoSmithKline plc U.K., Eli Lilly and Company U.S., Pfizer, Inc. U.S., Bristol-Myers Squibb U.S., F. Hoffmann-La Roche AG Genentech Switzerland, Johnson & Johnson Services, Inc. U.S., Teva Pharmaceutical Industries Ltd Israel, and Celgene Corporation U.S. to name a few.



In October 2016, U.S. Food and Drug Administration issued an accelerated approval notice for Eli Lilly and Company’s drug Lartruvo Olaratumab with Doxorubicin to treat certain types soft tissue carcinoma


Report Outline:



The report provides granular level information about the market size, regional market share and forecast from 2019-2025
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. Executive summary
2. Global Soft Tissue Sarcoma Treatment Market Introduction
2.1. Global Soft Tissue Sarcoma Treatment Market – Taxonomy
2.2. Global Soft Tissue Sarcoma Treatment Market –Definitions
2.2.1. Treatment Type
2.2.2. Distribution Channel
3. Global Soft Tissue Sarcoma Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Soft Tissue Sarcoma Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Soft Tissue Sarcoma Treatment Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.7. Global Soft Tissue Sarcoma Treatment Market – Recent Treatment Launches
4. Global Soft Tissue Sarcoma Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 – 2025
4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
4.2. Year-over-Year Y-o-Y Growth Analysis %
4.3. Market Oppurtunity Analysis
5. Global Soft Tissue Sarcoma Treatment Market, By Treatment Type, 2014 - 2018 and Forecast, 2019 - 2025
5.1. Targeted Therapy
5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Chemotherapy
5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
5.3. Anti-angiogenesis Drugs
5.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.3.3. Market Opportunity Analysis
5.4. Radiation Therapy Internal Radiation Therapy and External Radiation Therapy
5.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.4.3. Market Opportunity Analysis
6. Global Soft Tissue Sarcoma Treatment Market, By Disease Type, 2014 - 2018 and Forecast, 2019 - 2025
6.1. Local Sarcoma
6.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Regional Sarcoma
6.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
6.3. Metastatic Sarcoma
6.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.3.3. Market Opportunity Analysis
7. Global Soft Tissue Sarcoma Treatment Market Forecast, By Distribution Channel, 2014 - 2018 and Forecast, 2019 - 2025
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. Long-Term Care Centers
7.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
8. Global Soft Tissue Sarcoma Treatment Market Forecast, By Region, 2014 - 2018 and Forecast, 2019 - 2025
8.1. North America
8.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.5.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.5.3. Market Opportunity Analysis
8.6. Global Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Region, 2019 – 2025
9. North America Soft Tissue Sarcoma Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
9.1.1. Treatment Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
9.1.1.1. Targeted Therapy
9.1.1.2. Chemotherapy
9.1.1.3. Anti-angiogenesis drugs
9.1.1.4. Radiation Therapy
9.1.1.4.1. Internal Radiation Therapy
9.1.1.4.2. External Radiation Therapy
9.1.2. Disease Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
9.1.2.1. Local Sarcoma
9.1.2.2. Regional Sarcoma
9.1.2.3. Metastatic Sarcoma
9.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Long-Term Care Centers
9.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn Y-o-Y Growth % and Market Share %
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2019 – 2025
9.1.6. North America Soft Tissue Sarcoma Treatment Market Dynamics – Trends
10. Europe Soft Tissue Sarcoma Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
10.1.1. Treatment Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
10.1.1.1. Targeted Therapy
10.1.1.2. Chemotherapy
10.1.1.3. Anti-angiogenesis drugs
10.1.1.4. Radiation Therapy
10.1.1.4.1. Internal Radiation Therapy
10.1.1.4.2. External Radiation Therapy
10.1.2. Disease Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.2.1. Local Sarcoma
10.1.2.2. Regional Sarcoma
10.1.2.3. Metastatic Sarcoma
10.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Long-Term Care Centers
10.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2019 – 2025
10.1.6. Europe Soft Tissue Sarcoma Treatment Market Dynamics – Trends
11. Asia-Pacific Soft Tissue Sarcoma Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
11.1.1. Treatment Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
11.1.1.1. Targeted Therapy
11.1.1.2. Chemotherapy
11.1.1.3. Anti-angiogenesis drugs
11.1.1.4. Radiation Therapy
11.1.1.4.1. Internal Radiation Therapy
11.1.1.4.2. External Radiation Therapy
11.1.2. Disease Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.2.1. Local Sarcoma
11.1.2.2. Regional Sarcoma
11.1.2.3. Metastatic Sarcoma
11.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Long-Term Care Centers
11.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn,
Y-o-Y Growth %, and Market Share %
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2019 – 2025
11.1.6. Asia-Pacific Soft Tissue Sarcoma Treatment Market Dynamics – Trends
12. Latin America Soft Tissue Sarcoma Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
12.1.1. Treatment Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
12.1.1.1. Targeted Therapy
12.1.1.2. Chemotherapy
12.1.1.3. Anti-angiogenesis drugs
12.1.1.4. Radiation Therapy
12.1.1.4.1. Internal Radiation Therapy
12.1.1.4.2. External Radiation Therapy
12.1.2. Disease Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.2.1. Local Sarcoma
12.1.2.2. Regional Sarcoma
12.1.2.3. Metastatic Sarcoma
12.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Long-Term Care Centers
12.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2019 – 2025
12.1.6. Latin America Soft Tissue Sarcoma Treatment Market Dynamics – Trends
13. Middle East & Africa Soft Tissue Sarcoma Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
13.1.1. Treatment Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
13.1.1.1. Targeted Therapy
13.1.1.2. Chemotherapy
13.1.1.3. Anti-angiogenesis drugs
13.1.1.4. Radiation Therapy
13.1.1.4.1. Internal Radiation Therapy
13.1.1.4.2. External Radiation Therapy
13.1.2. Disease Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.2.1. Local Sarcoma
13.1.2.2. Regional Sarcoma
13.1.2.3. Metastatic Sarcoma
13.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Long-Term Care Centers
13.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
13.1.4.1. Gulf Cooperation Council GCC Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2019 – 2025
13.1.6. MEA Soft Tissue Sarcoma Treatment Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles Introduction, Financial Analysis, Treatment & Service Offerings, Key Developments, Strategies, and SWOT Analysis
14.2.1. GlaxoSmithKline plc U.K.
14.2.2. Eli Lilly and Company U.S.
14.2.3. Pfizer, Inc. U.S.
14.2.4. Bristol-Myers Squibb U.S.
14.2.5. F. Hoffmann-La Roche AG Switzerland
14.2.6. Johnson & Johnson Services, Inc. U.S.
14.2.7. Teva Pharmaceutical Industries Ltd Israel
14.2.8. Celgene Corporation U.S.
15. Research Methodology
16. Key Assumptions and Acronyms


Please fill the following form to know more details about this Report




RELATED PRODUCTS



CHOOSE A FORMAT


  •  Single User Price : $ 4400
  •  Enterprise User License : $ 6600
  •  Corporate User License : $ 8900

Have A Question ?


  DOWNLOAD SAMPLE



TESTIMONIALS

I am completely satisfied with the information given in the sample pages of the report and I am waiting for the affirmative response from my peers and colleagues to purchase it.hey answered to all my queries promptly. I am highly satisfied!!
John Keats
We received a very quick response to all our queries on the RTLS report and we were also given a free consult with analyst for 15 minutes. It is refreshing (and increasingly rare) to have a new company go the extra mile to win the confidence of the customer
Ernest Hemingway
I would like to express my gratitude for the excellent service received this morning from the support team. They acknowledged my concern of adding me to the secondary user's list immediately. Thank you for this excellent, speedy and thoughtful service
Jacob Watson

CUSTOM RESEARCH

Still haven't found what you're looking for ?
Speak to our Custom Research Team